LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "flt3 mutation" as a keyword



Photo from wikipedia

Molecular genetic profiling reveals novel association between FLT3 mutation and survival in glioma

Sign Up to like & get
recommendations! Published in 2020 at "Journal of Neuro-Oncology"

DOI: 10.1007/s11060-020-03567-9

Abstract: Recent molecular characterization of gliomas has uncovered somatic gene variation and DNA methylation changes that are associated with etiology, prognosis, and therapeutic response. Here we describe genomic profiling of gliomas assessed for associations between genetic… read more here.

Keywords: methylation; novel association; flt3 mutation; mgmt methylation ... See more keywords

Does NPM1 Mutation Have More Impact Than FLT3 on Response to Induction Chemotherapy in African‐American Patients With Acute Myeloid Leukemia?: 202

Sign Up to like & get
recommendations! Published in 2018 at "American Journal of Clinical Pathology"

DOI: 10.1093/ajcp/aqx121.201

Abstract: Methods: Sixteen cases of AML with mutated NPM1 were diagnosed at SUNY UMU over the course of last year. Reticulin staining was performed on either the bone marrow biopsy or clot section and results were… read more here.

Keywords: fibrosis; increased reticulin; flt3 mutation; induction ... See more keywords

Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia

Sign Up to like & get
recommendations! Published in 2022 at "Clinical Cancer Research"

DOI: 10.1158/1078-0432.ccr-21-3405

Abstract: Abstract Purpose: To evaluate efficacy and safety of venetoclax + azacitidine among treatment-naïve patients with FLT3-mutant acute myeloid leukemia. Patients and Methods: Data were pooled from patients enrolled in a phase III study (NCT02993523) that… read more here.

Keywords: flt3 mutation; azacitidine patients; acute myeloid; azacitidine ... See more keywords

Estimand Framework in AML Based on a Randomized, Placebo-Controlled, Phase 3 Study Investigating the Effect of Adding Midostaurin to Standard Chemotherapy in Patients with Newly Diagnosed AML without a FLT3 Mutation

Sign Up to like & get
recommendations! Published in 2018 at "Blood"

DOI: 10.1182/blood-2018-99-119394

Abstract: In the ongoing randomized, placebo-controlled, phase 3 study in patients with newly diagnosed FLT3-mutation-negative acute myeloid leukemia (AML; NCT03512197) investigating the effect of adding midostaurin to standard chemotherapy, event-free survival (EFS) is the primary endpoint.… read more here.

Keywords: estimand framework; treatment; effect; flt3 mutation ... See more keywords

Real World Data of FLT3 Mutation Testing Rates Among Indian Patients with Acute Myeloid Leukemia: An AI-Enabled Intervention to Improve Guideline-Compliant Care

Sign Up to like & get
recommendations! Published in 2024 at "Blood"

DOI: 10.1182/blood-2024-209677

Abstract: Background: Navya-Al is an online cancer informatics solution that leverages artificial intelligence (AI) and asynchronous expert review to provide individualized treatment plans for cancer patients. By analyzing NCCN Guidelines and expert recommendations, Navya-Al generates opinions… read more here.

Keywords: treatment; flt3 mutation; care; guideline ... See more keywords
Photo by nci from unsplash

Deep molecular response to gilteritinib to improve survival in FLT3 mutation-positive relapsed/refractory acute myeloid leukemia.

Sign Up to like & get
recommendations! Published in 2017 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2017.35.15_suppl.7003

Abstract: 7003Background: Gilteritinib, a highly selective FLT3/AXL inhibitor, has displayed antileukemic activity in FLT3 mutation-positive (FLT3mut+) relapsed/refractory (R/R) AML in the CHRYSALIS Phase I/... read more here.

Keywords: relapsed refractory; gilteritinib; mutation positive; deep molecular ... See more keywords

A phase II/III, multicenter, open-label, 3-arm study of gilteritinib, gilteritinib plus azacitidine, or azacitidine alone in the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia (AML) patients ineligible for intensive induction chemotherapy.

Sign Up to like & get
recommendations! Published in 2017 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2017.35.15_suppl.tps7068

Abstract: TPS7068Background: Gilteritinib, a highly selective, potent FLT3/AXL inhibitor, showed antileukemic activity with favorable tolerability in a Phase 1/2 trial of FLT3 mutation-positive (FLT3mut+) relapsed/refractory AML. In FLT3mut+ AML cell lines, gilteritinib plus azacitidine (AZA) inhibited… read more here.

Keywords: gilteritinib; phase; newly diagnosed; flt3 mutation ... See more keywords